These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 8669812)

  • 41. Development and characterization of monoclonal antibodies against human epidermal growth factor receptor in Balb/c mice.
    Baradaran B; Hosseini AZ; Majidi J; Farajnia S; Barar J; Saraf ZH; Abdolalizadeh J; Omidi Y
    Hum Antibodies; 2009; 18(1-2):11-6. PubMed ID: 19478394
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies.
    Nakazawa Y; Takagi S; Sato S; Oh-hara T; Koike S; Takami M; Arai H; Fujita N
    Cancer Sci; 2011 Nov; 102(11):2051-7. PubMed ID: 21824222
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Construction and in vivo evaluation of an anti-PSA x anti-CD3 bispecific antibody for the immunotherapy of prostate cancer.
    Katzenwadel A; Schleer H; Gierschner D; Wetterauer U; Elsässer-Beile U
    Anticancer Res; 2000; 20(3A):1551-5. PubMed ID: 10928069
    [TBL] [Abstract][Full Text] [Related]  

  • 44. B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors.
    Liu A; Hu P; Khawli LA; Epstein AL
    J Immunother; 2006; 29(4):425-35. PubMed ID: 16799338
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Engineering mouse monoclonal antibodies for cancer immunotherapy.
    Orlandi R
    Year Immunol; 1993; 7():69-73. PubMed ID: 8372514
    [No Abstract]   [Full Text] [Related]  

  • 46. High stability hybrids producing monoclonal antibodies against human C-reactive protein.
    Iturralde M; Coll J
    Rev Esp Fisiol; 1984 Sep; 40(3):279-87. PubMed ID: 6522796
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Development of an enzyme immunoassay for leukaemic cells using bifunctional antibodies.
    Nolan O; O'Kennedy R
    Year Immunol; 1993; 7():81-9. PubMed ID: 8372515
    [No Abstract]   [Full Text] [Related]  

  • 48. Antibodies against osteosarcoma and colon cancer.
    Embleton MJ; Brown A; Gunn B; Byers VS; Baldwin RW
    Behring Inst Mitt; 1984 May; (74):35-8. PubMed ID: 6591916
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A new murine monoclonal antibody against human hepatoma.
    Stein R; Wang ZF; Sharkey RM; Klein KM; Goldenberg DM
    Hybridoma; 1991 Apr; 10(2):255-67. PubMed ID: 1651901
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of matrix metalloproteinase 9 activation by a specific monoclonal antibody.
    Ramos-DeSimone N; Moll UM; Quigley JP; French DL
    Hybridoma; 1993 Aug; 12(4):349-63. PubMed ID: 8244415
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of the growth of human melanoma metastases in nude mice by melanoma-specific murine monoclonal antibody.
    Abdel-Wahab ZA; Darrow TL; Vervaert CE; Giannopoulou AA; Li W; Seigler HF
    Surg Oncol; 1992 Apr; 1(2):115-25. PubMed ID: 1341242
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Characteristics of two anti-tumour monoclonal antibody preparations.
    Price MR; Dennick RG; Fang CY; Hannant D; Embleton MJ; Gunn B; Baldwin RW
    Arch Geschwulstforsch; 1981; 51(4):302-9. PubMed ID: 6947720
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Monoclonal antibody LC85a against human lung adenocarcinoma].
    Xing PX; Xue KX; Cao S; Dong HY; Ling YL; Liu EX; Hou JC
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1985 Dec; 7(6):419-24. PubMed ID: 2940002
    [No Abstract]   [Full Text] [Related]  

  • 54. Crystallization of intact monoclonal antibodies.
    Harris LJ; Skaletsky E; McPherson A
    Proteins; 1995 Oct; 23(2):285-9. PubMed ID: 8592710
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Making monoclonal antibodies.
    Asai DJ; Wilder JK
    Methods Cell Biol; 1993; 37():57-74. PubMed ID: 8255250
    [No Abstract]   [Full Text] [Related]  

  • 56. Myeloma-specific antibodies: studies of their properties and their relationship to tumor immunity.
    Frikke MJ; Bridges SH; Lynch RG
    J Immunol; 1977 Jun; 118(6):2206-12. PubMed ID: 864258
    [No Abstract]   [Full Text] [Related]  

  • 57. Optimizing production of human monoclonal IgG antibodies by in vitro-primed human PBMC: influence of CD56+ NK cell depletion.
    Puhlmann CM; Anderer FA
    Hybridoma; 1995 Aug; 14(4):391-6. PubMed ID: 8522352
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Characterization of a monoclonal antibody recognizing a 138 kDa glioblastoma-associated antigen.
    Klaich GM; Kanter PM
    Anticancer Drugs; 1995 Feb; 6(1):45-52. PubMed ID: 7756683
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A rapid and efficient in vivo method for determining the biologic efficacy of monoclonal antibodies in animal models of cancer.
    Staquet K; Giles-Komar J
    Hybridoma (Larchmt); 2006 Apr; 25(2):68-74. PubMed ID: 16704306
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Murine monoclonal antibody development.
    Johnson DR
    Methods Mol Biol; 1995; 51():123-37. PubMed ID: 7581691
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.